LINC02389/miR-7-5p Regulated Cisplatin Resistance of Non-Small-Cell Lung Cancer via Promoting Oxidative Stress

Figure 3

(a) CCK-8 assay to evaluate the IC50 of A549 and A549-R (cisplatin resistant) to cisplatin. (b) LINC02389 expression in A549-R compared with A549. (c) Knockdown of LINC02389 expression in A549-R. (d) CCK-8 assay to evaluate the effect of LINC02389 knockdown in IC50 of A549-R to cisplatin. (e) UCSC genome browser to explore the H3K27ac enrichment. (f) H3K27ac expression in A549-R compared with A549. (g) H3K27ac expression in A549-R treated with C646. (h) LINC02389 expression in A549-R treated with C646. (i) ChIP assay to evaluate the enrichment of H3K27ac in the promoter region of LINC02389 in A549-R. (j) ChIP assay to evaluate the enrichment of H3K27ac in the promoter region of LINC02389 in A549-R treated with C646.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)